TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology announced a non-compliance incident involving Mr. Cho, a non-executive director, whose spouse sold shares during a black-out period without prior notification. The company is taking steps to prevent future incidents by enhancing compliance training and awareness among its directors and staff.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It focuses on developing innovative oncology therapies and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 4,153,490
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.25B
Learn more about 9966 stock on TipRanks’ Stock Analysis page.